Intrinsic Imaging
Intrinsic Imaging is a U.S.-based, full-service medical imaging core laboratory that delivers end-to-end imaging endpoints, blinded central reads, and AI/CAD validation services for pharmaceutical, biotechnology, medical device, and AI clinical-trial sponsors running Phase I–IV drug and Class I–III device trials globally.
- Company typePrivate
- Founded2010
- HeadquartersBolton, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Intrinsic Imaging does
Intrinsic Imaging is a full-service medical imaging core laboratory that supports pharmaceutical, biotechnology, medical device, and AI clinical-trial sponsors across Phase I–IV drug trials and Class I, II, and III device trials. The company provides end-to-end imaging services including protocol and charter design, site qualification and technologist training, centralized image collection and quality control, blinded independent central reads (single, double, and triple-read paradigms), endpoint adjudication, quantitative image analysis, biostatistics and 21 CFR Part 11-compliant data delivery, and regulatory submission support for the FDA, EMA, and PMDA. Its distinguishing infrastructure is a reader panel of 1,000+ board-certified, fellowship-trained physicians with documented sub-specialization across oncology, cardiology, CNS, gastroenterology, musculoskeletal, and ophthalmology, plus what the company describes as the only five-ISO-certified (and three FDA BIMO-inspected, zero-483) quality management system among imaging core labs. It also operates a specialized AI/CAD/Viewer validation practice built around multi-case multi-reader observer performance studies, with 55 large MRMC AI/CAD trials and tens of thousands of case reviews reported.
The business operates on a project/contract-based professional-services model: engagements are custom-quoted per study via a 'Request a Proposal' motion, with pricing varying by therapeutic area, phase, modality, reader count, case volume, and regulatory scope. Acquisition is enterprise-driven direct sales to clinical-trial sponsors — no channel partners, resellers, or self-serve channels — supported by a website and a leadership team with deep CRO/clinical-research pedigrees (CEO Todd A. Joron previously ran a $165M PAREXEL Perceptive Informatics P&L; CMO Dr. Amit Mehta is a Harvard/MGH-trained interventional radiologist and Builders VC General Partner). After being sold to WCG Clinical in 2021 for approximately $80 million, the business was reacquired by its founders in 2026 and returned to independent operation from its headquarters in Bolton, Massachusetts.
Intrinsic Imaging firmographics
Firmographics- Name
- Intrinsic Imaging
- Legal name
- Intrinsic Imaging, LLC
- Website
- https://intrinsicimaging.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Intrinsic Imaging is a U.S.-based, full-service medical imaging core laboratory that delivers end-to-end imaging endpoints, blinded central reads, and AI/CAD validation services for pharmaceutical, biotechnology, medical device, and AI clinical-trial sponsors running Phase I–IV drug and Class I–III device trials globally.
- Ownership category
- akta.pro rank
Intrinsic Imaging industry classification
Industry- Product category
- Medical Imaging Core Lab Services
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Imaging Core Labs & Clinical Endpoint Adjudication (HLAGAEAH)
- akta.pro secondary industries
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Imaging Interoperability & Standards Enablement (DICOM/HL7/FHIR/IHE) (HLACALAJ)
Keywords
Where Intrinsic Imaging is headquartered
LocationHeadquarters
- HQ city
- Bolton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Intrinsic Imaging business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Medical Imaging Core Lab Services: Intrinsic Imaging generates revenue by providing comprehensive medical imaging core lab services to pharmaceutical, biotechnology, medical device, and AI clinical trial sponsors. Services include imaging protocol development, centralized image collection and QC, blinded independent reads, endpoint adjudication, quantitative image analysis, and regulatory submission support. Revenue is likely project/contract-based, driven by the number and complexity of clinical trials supported. The company operates on a per-study or per-service contractual model typical of core labs serving pharma/biotech clients.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Custom project-based pricing for clinical trial imaging services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Intrinsic Imaging product offering
Product offeringCore offering
Intrinsic Imaging is a full-service medical imaging core laboratory that provides comprehensive imaging services to support Phase I-IV clinical trials and Class I, II, and III medical device trials. Services include imaging protocol and charter design, site qualification and training, centralized image collection and quality control, blinded independent central reads (single, double, triple-read paradigms), endpoint adjudication, quantitative image analysis, biostatistics, and regulatory submission support for FDA, EMA, and PMDA. The company is also a world leader in conducting stand-alone and multi-case multi-reader (MRMC) observer performance studies to evaluate AI/CAD/Viewer software.
Product overview
Intrinsic Imaging is a full-service medical imaging core lab providing comprehensive imaging services for Phase I-IV clinical trials and Class I-III medical device trials. The core offering includes AI/CAD studies as a specialized service for FDA device clearance, independent central reads by sub-specialty radiologists, and therapeutic area-specific imaging services across six major areas: Oncology, Cardiology, Central Nervous System, Gastroenterology, Musculoskeletal, and Ophthalmology. The company operates with a team of 1000+ board-certified, fellowship-trained physicians and supports clinical trials in 65+ countries.
Differentiator
Problem solved
Functional benefit
Products and services
- Medical Imaging Core Lab Services Full-service medical imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, and III medical device trials, including imaging protocol development, site qualification, independent central reads, and endpoint adjudication for pharmaceutical, biotechnology, medical device, and AI clinical trial sponsors.
- AI / CAD Studies
Quantifiable outcome
- 55 large MRMC AI/CAD trials completed with experience managing 10,000–30,000 case reviews
- +3 more outcomes
Companies that use Intrinsic Imaging
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Intrinsic Imaging technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Intrinsic Imaging partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- WCG ClinicalmajorIntrinsic Imaging was acquired by WCG Clinical in 2021 in a transaction valued at approximately $80 million. The acquisition integrated Intrinsic Imaging's expertise into WCG Clinical's Scientific and Regulatory Division. Following the acquisition, company leadership continued to operate the business within WCG Clinical. In 2026, company founders Todd Joron and Dr. Amit Mehta reacquired Intrinsic Imaging, returning it to independent ownership.
Scale indicators6 records
Recent moves7 records
Expansion highlights4 records
Intrinsic Imaging competitors and assessment
Company assessmentDirect peers
- Clario: Clario (formed from the merger of Bioclinica and ERT) is the largest dedicated imaging core lab and eCOA provider for clinical trials, offering blinded independent central reads, MRMC studies, and therapeutic-area imaging services that directly overlap Intrinsic Imaging's core offering.
- IXICO: IXICO provides imaging biomarker and central read services for neuroscience and oncology clinical trials, with deep expertise in MRMC-style study design and AI-assisted image analysis — directly comparable to Intrinsic's CNS and AI/CAD work.
- Median Technologies: Median Technologies runs an imaging core lab (iCRO) for oncology clinical trials, providing independent central reads, RECIST-based response assessment, and AI-driven image analysis — overlapping directly with Intrinsic's oncology imaging and AI/CAD capabilities.
- Calyx: Calyx (which acquired VirtualScopics) provides medical imaging core lab services and AI-enabled quantitative imaging for clinical trials, with similar therapeutic-area breadth and FDA submission support to Intrinsic Imaging.
- Worldcare Clinical: Worldcare Clinical is a dedicated imaging core lab serving pharma, biotech, and medical device sponsors with central reads, MRMC studies, and regulatory submission support, comparable in scope and customer base to Intrinsic Imaging.
Broad incumbents
- ICON plc: ICON plc is a top-5 global CRO that bundles imaging core lab and central read services into its full-service Phase I-IV offering, representing a broader incumbent alternative to using a stand-alone imaging core lab like Intrinsic.
- Medpace: Medpace is a mid-to-large CRO with an in-house imaging core lab capability supporting its full-service clinical trial business, competing with Intrinsic for both imaging endpoints and broader trial outsourcing decisions.
- IQVIA: IQVIA is the world's largest CRO and offers integrated imaging and central laboratory services as part of its full-service trial platform, giving it significant bundling power against stand-alone imaging core labs like Intrinsic.
- Fortrea: Fortrea (spun out of Labcorp's drug development business) is a global CRO with central imaging and endpoint adjudication services that overlap Intrinsic's offering and compete for pharma/biotech sponsor budgets.
Emerging players
- Philips BioTel Research: Philips BioTel Research provides imaging core lab and cardiac monitoring services for clinical trials, with growing AI-enabled cardiac imaging capabilities that intersect Intrinsic's cardiology and AI/CAD practice areas.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Intrinsic Imaging social profiles
Digital presenceIntrinsic Imaging compliance and trust
Trust signalCompliance6 records
Intrinsic Imaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intrinsic Imaging leadership team
Management profileNumber of profiles
Profiles4 records
Intrinsic Imaging funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intrinsic Imaging M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intrinsic Imaging
What does Intrinsic Imaging do?
Intrinsic Imaging is a full-service medical imaging core laboratory that provides comprehensive imaging services to support Phase I-IV clinical trials and Class I, II, and III medical device trials. Services include imaging protocol and charter design, site qualification and training, centralized image collection and quality control, blinded independent central reads (single, double, triple-read paradigms), endpoint adjudication, quantitative image analysis, biostatistics, and regulatory submission support for FDA, EMA, and PMDA. The company is also a world leader in conducting stand-alone and multi-case multi-reader (MRMC) observer performance studies to evaluate AI/CAD/Viewer software.
Is Intrinsic Imaging a public or private company?
Intrinsic Imaging is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Intrinsic Imaging founded?
Intrinsic Imaging was founded in 2010. It employs 51 to 100 people.
Where is Intrinsic Imaging based?
Intrinsic Imaging is headquartered in Bolton, United States, in the North America region.
How does Intrinsic Imaging make money?
One revenue line is on record: medical Imaging Core Lab Services.
Who are Intrinsic Imaging's main competitors?
Direct peers on record are Clario, IXICO, Median Technologies, Calyx and Worldcare Clinical. Broad incumbents are ICON plc, Medpace, IQVIA and Fortrea. Philips BioTel Research is listed as an emerging player.
Does Intrinsic Imaging have an API?
No public API is recorded for Intrinsic Imaging.
What industry is Intrinsic Imaging in?
Intrinsic Imaging's product category is Medical Imaging Core Lab Services. Its primary akta.pro industry code is HLAGAEAH, Imaging Core Labs & Clinical Endpoint Adjudication, with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 621511 and its SIC code is 8071.